Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
P378. Safety of adalimumab in global clinical trials of ulcerative colitis patients
Authors:

J.-F. Colombel1, S. Ghosh2, W. Sandborn3, G. Van Assche4, W. Reinisch5, A. Lazar6, S. Eichner7, B. Huang7, A. Robinson7, R. Thakkar7, 1Centre Hospitalier Universitaire de Lille, Lille, France, 2University of Calgary, Calgary, Canada, 3University of California San Diego, La Jolla, United States, 4University of Toronto, Toronto, Canada, 5Medical University Vienna, Vienna, Austria, 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 7Abbott Laboratories, Abbott Park, United States

P378

Early hs-CRP normalization and mucosal healing are effective predictors for 1-year mucosal healing

Authors:

J. Tang*, X. Gao, M. Zhi, P. Hu

The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China

P379.

Predictors of response to medical treatment in Crohn's disease patients with intestinal obstruction

Authors:

N. Ben Mustapha, A. Labidi, M. Serghini, Y. Kardous, M. Fekih, J. Boubaker, A. Filali, La Rabta Hospital, Gastroenterology A, Tunis, Tunisia

P379. Implications of evolving anti‑TNF treatment patterns in a tertiary referral centre: Results of 1457 patient-years follow-up
P379. Safety and efficacy of laquinimod in inducing clinical and biochemical improvement in active Crohn's disease: Results of an exploratory trial
Authors:

G. D'Haens1, J.-F. Colombel2, W. Sandborn3, P. Rutgeerts4, B. Feagan5, 1University of Amsterdam, Amsterdam, Netherlands, 2Centre Hospitalier Universitaire (CHU) de Lille, Lille, France, 3University of California San Diego, United States, 4Catholic University of Leuven, Belgium, 5University of Western Ontario, Canada

P379. Systematic review: Clostridium difficile and IBD
P379

Prolonged and repeated steroid exposure in inflammatory bowel disease: National population based study

Authors:

V. Chhaya*1, S. Saxena2, E. Cecil2, V. Subramanian3, V. Curcin4, A. Majeed2, R. Pollok1

1St George's University of London, Gastroenterology, London, United Kingdom, 2Imperial College London, Primary care and Public Health, London, United Kingdom, 3St James' University Hospital, Gastroenterology, Leeds, United Kingdom, 4King's College, Computing, London, United Kingdom

P380.

Predictors of clinical response to immunomodulators in moderate to severe Crohn's disease

Authors:

J.S. Koo, B. Keum, B.J. Lee, Y.J. Jeen, J.H. Choi, Korea University College of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of

P380. Incidence of Clostridium difficile infection in IBD patients compared to oncology and immunocompetent patients
P380. Oral beclomethasone dipropionate in the treatment of chronic refractory pouchitis
P380. Safety and efficacy of bolus administered ferric carboxymaltose (500 mg) in the treatment of iron deficiency anaemia in IBD patients
Authors:

D. Jakobsen1, M. Wiesenthal2, F. Hartmann3, A. Dignass4, S. Weber-Mangal5, J. Stein2, 11Krankenhaus Sachsenhausen, Crohn Colitis Center, Frankfurt, Germany, 2Crohn Colitis Zentrum Rhein-Main, Frankfurt, Germany, 3Marien Krankenhaus, Frankfurt, Germany, 4Apaglesion Markus Krankenhaus, Frankfurt, Germany, 5Vifor Pharma Germany, Munich, Germany

P380

Risk Factors for Drug-induced Lupus secondary to Anti-tumor Necrosis Factor Agents used in Inflammatory Bowel Disease: A Multicenter Case-control Study in Madrid

Authors:

J.L. Perez-Calle1, E. De La Fuente*1, C. Taxonera2, I. Blazquez3, V. Opio4, M. Villafruela5, D. Olivares2, E. San Miguel4, P. Lopez1, E. Perez6, C. Fernandez1

1Universitary Hospital Fundacion Alcorcon, Gastroenterology, Madrid, Spain, 2H Clinico San Carlos, IBD Unit, Madrid, Spain, 3Hospital Puerta de Hierro, Gastroenterology, Majadahonda, Madrid, Spain, 4Getafe University Hospital, Gastroenterology, Madrid, Spain, 5Hospital de Alcalá de Henares, Gastroenterology, Madrid, Spain, 6Universitary Hospital Fundacion Alcorcon, Investigation Unit, Madrid, Spain

P381.

Predictors and frequency of anti-TNF dose escalation in patients with inflammatory bowel disease

Authors:

N. Viazis, T. Koukouratos, J. Anastasiou, E. Saprikis, G. Kechagias, K. Katopodi, M. Mela, D. Karamanolis, Evangelismos Hospital, Gastroenterology Department, Athens, Greece

P381. Place of immunosuppressive agents in management of IBD in a developing country in era of anti TNF strategies according to Moroccan unit experience
P381. Role of fecal calprotection in predicting ileocolonic endoscopic recurrence in postoperative Crohn's disease
Authors:

C. Primas1, G. Frühwald1, S. Angelberger1, D. Allerstorfer1, P. Papay1, A. Eser1, C. Gratzer1, C. Dejaco1, W. Reinisch1, G. Novacek1, H. Vogelsang1, 1Medical University of Vienna, Internal Medicin III, Vienna, Austria

P381. The impact of intestinal infections in IBD patients: Experience from an Italian tertiary referral centre
P381

Feasibility and value of stool anti-TNF measurement in IBD patient in loose of response: a preliminary study

Authors:

S. Paul1, M. Rinaudo1, C. Jarlot2, E. del Tedesco2, J.M. Phelip2, X. Roblin*2

1University of Saint Etienne, Immunology, Saint Etienne, France, 2University Hospital, Gastroenterology, Saint Etienne, France

P382.

Predictor of effect of oral tacrolimus on refractory ulcerative colitis

Authors:

A. Ito, B. Iizuka, M. Takahashi, T. Omori, M. Yonezawa, K. Shiratori, Tokyo Women's Medical University, Department of Gastroenterology, Tokyo, Japan

P382. Cryptosporidiosis and inflammatory bowel disease
P382. Inflammatory bowel disease itself is a more important risk factor for impaired health-related quality of life than non-adherence to medical therapy